We are describing a not yet documented cause for mucopurulent endocervicitis which is triggered by the reaction of neutrophil granulocytes against lactobacilli and is referred to as “lactobacillary endocervicitis” in this contribution. Lactobacilli are a normal component of the vaginal flora. Samples from 16 chronic cervicitis were collected by swabbing the portion. Direct microscopy of the samples showed Gram-positive rods among polymorphonuclear cells (more than 10 per high-power field). Many of the polymorphonuclear cells try to phagocytize the rods All samples tested negative by polymerase chain reaction (PCR) for Chlamydia trachomatis , Neisseria gonorrhoea , Ureaplasma urealyticum , Ureaplasma , M.hominis and M.genitalium . Random samples were also tested for Trichomonas vaginalis and/or human papillomavirus by PCR and resulted negative. None of the women showed signs of bacterial vaginosis. Neither clue cells (by microscopy) nor Gardnerella vaginalis (by culture) were detected in these cases. The 16 observed patients with lactobacillary endocervicitis
{"title":"https://researchopenworld.com/lactobacillary-endocervicitis-a-novel-cause-of-chronic-cervicitis/#","authors":"T. Krech, Sandra Kilgus-Hawelski","doi":"10.31038/awhc.2019266","DOIUrl":"https://doi.org/10.31038/awhc.2019266","url":null,"abstract":"We are describing a not yet documented cause for mucopurulent endocervicitis which is triggered by the reaction of neutrophil granulocytes against lactobacilli and is referred to as “lactobacillary endocervicitis” in this contribution. Lactobacilli are a normal component of the vaginal flora. Samples from 16 chronic cervicitis were collected by swabbing the portion. Direct microscopy of the samples showed Gram-positive rods among polymorphonuclear cells (more than 10 per high-power field). Many of the polymorphonuclear cells try to phagocytize the rods All samples tested negative by polymerase chain reaction (PCR) for Chlamydia trachomatis , Neisseria gonorrhoea , Ureaplasma urealyticum , Ureaplasma , M.hominis and M.genitalium . Random samples were also tested for Trichomonas vaginalis and/or human papillomavirus by PCR and resulted negative. None of the women showed signs of bacterial vaginosis. Neither clue cells (by microscopy) nor Gardnerella vaginalis (by culture) were detected in these cases. The 16 observed patients with lactobacillary endocervicitis","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74103921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Migraine is a debilitating neurological primary headache disorder characterized by recurring unipolar headaches lasting 4–72 hours with accompaniment of nausea and sensory sensitivities. Migraine is the most common headache disorder resulting in seeking of medical care [1, 2], in addition to being one of the most debilitating chronic disease conditions in terms of both morbidity and lost economic productivity. Migraine incidence has been observed since ancient times to disproportionately affect women, and most current epidemiological assessments put current incidence estimates at 12% overall for US populations, with an incidence of 18% in women and 6% in men when stratified by sex. This dimorphism of incidence is crucial when assessing overall health of a community, specifically when concerning women’s health and therefore must be taken into consideration when developing both clinical and basic models of migraine to enact the best possible outcomes of combined translational research efforts. While major recent advances have been made in the field of pharmacologic intervention for migraine with the recent approval of the anti CGRP and anti CGRP receptor antibody medications, prohibitive cost and limited access have made older treatments, such as the triptans and NSAIDs, still the most commonly utilized medications to combat migraine attacks. Current preclinical research models are heavily interested in modulation of the neuropeptide CGRP, and the phenomenon of cortical spreading depression (CSD), believed to be the underlying trigger of migraine with aura, via pharmacological intervention. Modulations of these phenomena has found to be correlated with menstrual events in women, tying back to the overarching theme of higher morbidity in women. With the advent of pharmacogenomics and personalized medicine, a new epoch of potential customizable treatments looms on the horizon, endearing those afflicted with this severely debilitating condition a new glimmer of hope as research progresses into its next phase. Acronyms: AMPP: American Migraine Prevalence and Prevention study. NIH: National Institute of Health. ICHD-3: International Classification of Headache Disorders, 3rd edition. NHIS: National Health Interview Survey. NSAID: Non-Steroidal Anti-Inflammatory Drug. CGRP: Calcitonin Gene Related Peptide. 5HT1: 5-Hydroxytryptamine (Serotonin) Receptor, Subfamily 1. FDA: Food and Drug Administration. CNS: Central Nervous System. MOH: Medication Overuse Headache. PGE2: Prostaglandin E2. CSD: Cortical Spreading depression. fMRI: Functional Magnetic Resonance Imaging. GWAS: Genome Wide Association Study. SNP: Single Nucleotide Polymorphism.
{"title":"https://researchopenworld.com/migraine-a-review-of-basic-clinical-and-translational-approaches-to-new-treatment/#","authors":"Jared Wahl, T. Vanderah","doi":"10.31038/awhc.2019263","DOIUrl":"https://doi.org/10.31038/awhc.2019263","url":null,"abstract":"Migraine is a debilitating neurological primary headache disorder characterized by recurring unipolar headaches lasting 4–72 hours with accompaniment of nausea and sensory sensitivities. Migraine is the most common headache disorder resulting in seeking of medical care [1, 2], in addition to being one of the most debilitating chronic disease conditions in terms of both morbidity and lost economic productivity. Migraine incidence has been observed since ancient times to disproportionately affect women, and most current epidemiological assessments put current incidence estimates at 12% overall for US populations, with an incidence of 18% in women and 6% in men when stratified by sex. This dimorphism of incidence is crucial when assessing overall health of a community, specifically when concerning women’s health and therefore must be taken into consideration when developing both clinical and basic models of migraine to enact the best possible outcomes of combined translational research efforts. While major recent advances have been made in the field of pharmacologic intervention for migraine with the recent approval of the anti CGRP and anti CGRP receptor antibody medications, prohibitive cost and limited access have made older treatments, such as the triptans and NSAIDs, still the most commonly utilized medications to combat migraine attacks. Current preclinical research models are heavily interested in modulation of the neuropeptide CGRP, and the phenomenon of cortical spreading depression (CSD), believed to be the underlying trigger of migraine with aura, via pharmacological intervention. Modulations of these phenomena has found to be correlated with menstrual events in women, tying back to the overarching theme of higher morbidity in women. With the advent of pharmacogenomics and personalized medicine, a new epoch of potential customizable treatments looms on the horizon, endearing those afflicted with this severely debilitating condition a new glimmer of hope as research progresses into its next phase. Acronyms: AMPP: American Migraine Prevalence and Prevention study. NIH: National Institute of Health. ICHD-3: International Classification of Headache Disorders, 3rd edition. NHIS: National Health Interview Survey. NSAID: Non-Steroidal Anti-Inflammatory Drug. CGRP: Calcitonin Gene Related Peptide. 5HT1: 5-Hydroxytryptamine (Serotonin) Receptor, Subfamily 1. FDA: Food and Drug Administration. CNS: Central Nervous System. MOH: Medication Overuse Headache. PGE2: Prostaglandin E2. CSD: Cortical Spreading depression. fMRI: Functional Magnetic Resonance Imaging. GWAS: Genome Wide Association Study. SNP: Single Nucleotide Polymorphism.","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82842284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Seppälä, Ala-Nissilä Seija, Joronen Kirsi, L. Maren, Kauppila Marjo, Hautaniemi Soili, Rantanen Virpi
Objectives: To investigate how common incontinence problem is and how it could be detected in an unselected population. Methods: Cross-sectional study in primary care population. A population survey of women born in 1948 or 1950 and living in a municipality with 19,535 inhabitants in south-western Finland in 2017. Main outcome measures were i ncidence of urinary or faecal incontinence. Results: After analyzing the questionnaires and research findings, we found that urinary incontinence is a common phenomenon, reported by 50.3% of participants. According to the Urinary Incontinence Severity Score (UISS), 12.7% of them believed that the degree of disability was remarkable, and according to the Visual Analogue Scale (VAS), 18.3% considered the degree of disability to be difficult. In this study obesity was the most common feature affecting urinary incontinence. Conclusion: Urinary incontinence is a common problem and will increase as the population ages. It can deteriorate a person’s quality of life, increase her need of care and involve considerable costs. Preventing the problem and treating it as early as possible in primary health-care is both reasonable and saves time and money. Urinary incontinence is a common problem in the ageing female population. Many women are ashamed of their incontinence and do not even mention it during the GP’s consultation. Preventing the problem and treating it as early as possible in primary healthcare is important.
{"title":"https://researchopenworld.com/gps-should-actively-ask-about-symptoms-of-urinary-or-faecal-incontinence-in-ageing-female-patients/#","authors":"T. Seppälä, Ala-Nissilä Seija, Joronen Kirsi, L. Maren, Kauppila Marjo, Hautaniemi Soili, Rantanen Virpi","doi":"10.31038/awhc.2019264","DOIUrl":"https://doi.org/10.31038/awhc.2019264","url":null,"abstract":"Objectives: To investigate how common incontinence problem is and how it could be detected in an unselected population. Methods: Cross-sectional study in primary care population. A population survey of women born in 1948 or 1950 and living in a municipality with 19,535 inhabitants in south-western Finland in 2017. Main outcome measures were i ncidence of urinary or faecal incontinence. Results: After analyzing the questionnaires and research findings, we found that urinary incontinence is a common phenomenon, reported by 50.3% of participants. According to the Urinary Incontinence Severity Score (UISS), 12.7% of them believed that the degree of disability was remarkable, and according to the Visual Analogue Scale (VAS), 18.3% considered the degree of disability to be difficult. In this study obesity was the most common feature affecting urinary incontinence. Conclusion: Urinary incontinence is a common problem and will increase as the population ages. It can deteriorate a person’s quality of life, increase her need of care and involve considerable costs. Preventing the problem and treating it as early as possible in primary health-care is both reasonable and saves time and money. Urinary incontinence is a common problem in the ageing female population. Many women are ashamed of their incontinence and do not even mention it during the GP’s consultation. Preventing the problem and treating it as early as possible in primary healthcare is important.","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91278497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Amani, S. K. Nolna, Mireille Ndje Ndje, C. B. Ndongo, Marceline, Djuidje Ngounoue, B. A. Tiedeu, R. Leke
Cervical cancer is the second most frequent type of cancer in Cameroon [1]. More than 7.1 million Cameroonian women aged 15 and above are at risk of this disease [2]. In the past ten years, various pilot projects have demonstrated the efficacy and acceptability of Gardasil TM, the vaccine against Human Papillomavirus (HPV) [3,4]. Based on these successful demonstration phases, with the support of the Global Alliance for Vaccines and Immunization (GAVI), the HPV vaccine is finally being implemented countrywide by the Ministry of Public Health. The main objective of the vaccine roll-out will be to immunize at least 80% of 9-year-old girls, and thus reduce the morbidity and mortality due to cervical cancer and other HPV-related infections in Cameroon.
{"title":"https://researchopenworld.com/social-media-controversy-affecting-the-introduction-of-hpv-vaccination-for-young-girls-in-cameroon/#","authors":"A. Amani, S. K. Nolna, Mireille Ndje Ndje, C. B. Ndongo, Marceline, Djuidje Ngounoue, B. A. Tiedeu, R. Leke","doi":"10.31038/awhc.2019255","DOIUrl":"https://doi.org/10.31038/awhc.2019255","url":null,"abstract":"Cervical cancer is the second most frequent type of cancer in Cameroon [1]. More than 7.1 million Cameroonian women aged 15 and above are at risk of this disease [2]. In the past ten years, various pilot projects have demonstrated the efficacy and acceptability of Gardasil TM, the vaccine against Human Papillomavirus (HPV) [3,4]. Based on these successful demonstration phases, with the support of the Global Alliance for Vaccines and Immunization (GAVI), the HPV vaccine is finally being implemented countrywide by the Ministry of Public Health. The main objective of the vaccine roll-out will be to immunize at least 80% of 9-year-old girls, and thus reduce the morbidity and mortality due to cervical cancer and other HPV-related infections in Cameroon.","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76581534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Midlife women are experiencing increased rates of opioid use disorder (OUD) [1] and fatal overdose in the United States (US) [2]. Rates of opioid-related mortality have increased more rapidly among women than men [3], and when stratified by age, the increase in opioid-related mortality is particularly notable among middle-aged women [4]. Unique risk factors for opioid misuse and opioid use disorder (OUD) in women have been identified, including higher pain levels and increased opioid withdrawal symptoms [5] among women with OUD and higher rates of psychological comorbidities [6,7]. In addition, midlife women with co-occurring chronic pain and menopausal symptoms experience increased rates of risky opioid use including long-term opioid use, high-dose opioid use, and coprescription of CNS-depressants and opioids [8]. Thus, addressing pain, menopausal symptoms, and psychological comorbidities may help reduce rates of OUD and ultimately prevent fatal overdose among midlife women.
{"title":"https://researchopenworld.com/midlife-women-and-the-opioid-crisis-commentary-on-the-role-of-integrative-health/#","authors":"L. Taylor-Swanson, S. Simonsen, M. Koithan","doi":"10.31038/awhc.2019261","DOIUrl":"https://doi.org/10.31038/awhc.2019261","url":null,"abstract":"Midlife women are experiencing increased rates of opioid use disorder (OUD) [1] and fatal overdose in the United States (US) [2]. Rates of opioid-related mortality have increased more rapidly among women than men [3], and when stratified by age, the increase in opioid-related mortality is particularly notable among middle-aged women [4]. Unique risk factors for opioid misuse and opioid use disorder (OUD) in women have been identified, including higher pain levels and increased opioid withdrawal symptoms [5] among women with OUD and higher rates of psychological comorbidities [6,7]. In addition, midlife women with co-occurring chronic pain and menopausal symptoms experience increased rates of risky opioid use including long-term opioid use, high-dose opioid use, and coprescription of CNS-depressants and opioids [8]. Thus, addressing pain, menopausal symptoms, and psychological comorbidities may help reduce rates of OUD and ultimately prevent fatal overdose among midlife women.","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"9 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91503666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"https://researchopenworld.com/preparing-nursing-students-to-meet-public-expectations-while-preserving-professional-values-mind-genomics-cartography-of-the-publics-voice/#","authors":"","doi":"10.31038/awhc.2019262","DOIUrl":"https://doi.org/10.31038/awhc.2019262","url":null,"abstract":"","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73430463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maternal prenatal weight data can be used to estimate infant birth weight, connect weight concerns of the women before and after pregnancy, and prevent offspring obesity. Prenatal weight data can be interpreted in relation to many contexts, such as BMI, weight loss or gain, body fat, and patient perspectives. The primary goals for weight management during pregnancy include helping pregnant women achieve an optimal weight but to avoid excessive gestational weight gain. To prevent excessive gestational weight gain among pregnant women, healthcare providers can focus on utilizing integrated and inter professional collaborative team care approach, the 5A’s method for lifestyle counseling, and self-monitoring strategy to empower pregnant women for behavioral change. Prenatal weight management is important for a healthy pregnancy with short- and long-term health implications for the mother and the baby.
{"title":"https://researchopenworld.com/prenatal-weight-management-what-can-care-providers-do-to-prevent-maternal-excessive-weight-gain/#","authors":"C. Shieh","doi":"10.31038/awhc.2019253","DOIUrl":"https://doi.org/10.31038/awhc.2019253","url":null,"abstract":"Maternal prenatal weight data can be used to estimate infant birth weight, connect weight concerns of the women before and after pregnancy, and prevent offspring obesity. Prenatal weight data can be interpreted in relation to many contexts, such as BMI, weight loss or gain, body fat, and patient perspectives. The primary goals for weight management during pregnancy include helping pregnant women achieve an optimal weight but to avoid excessive gestational weight gain. To prevent excessive gestational weight gain among pregnant women, healthcare providers can focus on utilizing integrated and inter professional collaborative team care approach, the 5A’s method for lifestyle counseling, and self-monitoring strategy to empower pregnant women for behavioral change. Prenatal weight management is important for a healthy pregnancy with short- and long-term health implications for the mother and the baby.","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80805226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James Whitehall, Phillip Barnden, M. Rana, L. Wieland, D. Gillespie, Oliver Charlton, Me Cooper, Vedant Dave, Tom Hall, Sean Hanly, Sophie Higham, Gajanth, Sivapalan, Samantha Tripp, Gemma Walmsley, Samuel Watson, J. Whitehall
1Data analysis, writer, Paediatrics, Western Sydney University, Australia 2Programme organiser, Programme Officer, Symbiosis International, Bangladesh 3Programme organiser, Associate Programme Director, Mennonite Central Committee, Bangladesh 4Supervisor, Paediatrics, Western Sydney University, Australia 5Investigator Paediatrics, Western Sydney University, Australia 6Programme Director, Analysis and Writer Paediatrics, Western Sydney University, Australia
{"title":"https://researchopenworld.com/perinatal-and-child-mortality-under-nutrition-and-cerebral-palsy-a-cross-sectional-survey-in-rural-bangladesh/#","authors":"James Whitehall, Phillip Barnden, M. Rana, L. Wieland, D. Gillespie, Oliver Charlton, Me Cooper, Vedant Dave, Tom Hall, Sean Hanly, Sophie Higham, Gajanth, Sivapalan, Samantha Tripp, Gemma Walmsley, Samuel Watson, J. Whitehall","doi":"10.31038/awhc.2019254","DOIUrl":"https://doi.org/10.31038/awhc.2019254","url":null,"abstract":"1Data analysis, writer, Paediatrics, Western Sydney University, Australia 2Programme organiser, Programme Officer, Symbiosis International, Bangladesh 3Programme organiser, Associate Programme Director, Mennonite Central Committee, Bangladesh 4Supervisor, Paediatrics, Western Sydney University, Australia 5Investigator Paediatrics, Western Sydney University, Australia 6Programme Director, Analysis and Writer Paediatrics, Western Sydney University, Australia","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80089114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"https://researchopenworld.com/perinatal-mental-health-care-across-the-globe/#","authors":"","doi":"10.31038/awhc.2019251","DOIUrl":"https://doi.org/10.31038/awhc.2019251","url":null,"abstract":"","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76564398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"https://researchopenworld.com/microarray-testing-for-symmetrical-intrauterine-growth-retardation/#","authors":"","doi":"10.31038/awhc.2019243","DOIUrl":"https://doi.org/10.31038/awhc.2019243","url":null,"abstract":"","PeriodicalId":93266,"journal":{"name":"Archives of women health and care","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78055537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：